drugset
drugset / Trial / NCT00367393

Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis

NCT00367393 ↗

Phase 4 Completed 41 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of steroid-damaged skin and disease control.

Timeline

Start
2006-03
Primary completion
2007-12
Completion
2007-12

Publications

  • Background Reference: Thaci D et al TBD. CORTICOSTEROID-INDUCED SKIN DAMAGE IMPROVED WITH PIMECROLIMUS CREAM 1% TREATMENT: A 1-YEAR STUDY IN ADULTS WITH ATOPIC ECZEMA. European Academy of Dermatology and Venereology - 17th Congress. 2008; www.eadv.org

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimecrolimus Small molecule 1 % —

Indications

atopic eczema